US Edition
Survival in Small-Cell Lung Cancer Improved With Cytotoxic Add-On to Immunotherapy
Summary by MedPage Today
2 Articles
2 Articles
All
Left
Center
1
Right
MedPage TodayReposted by 
Anti-Aging, Acupuncture and Health News
Anti-Aging, Acupuncture and Health NewsSurvival in Small-Cell Lung Cancer Improved With Cytotoxic Add-On to Immunotherapy
(MedPage Today) -- CHICAGO -- Patients with extensive-stage small-cell lung cancer (SCLC) lived significantly longer with the addition of cytotoxic agent lurbinectedin (Zepzelca) to maintenance immunotherapy, a large randomized trial showed...
·New York, United States
Read Full ArticleCoverage Details
Total News Sources2
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
